Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Coronary Artery Disease V: Surgical Management

Coronary Artery Disease V: Surgical Management

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Acute Coronary Syndrome IV: Interprofessional Care

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...

Acute Coronary Syndrome II: Pathophysiology and clinical manifestations

Acute Coronary Syndrome II: Pathophysiology and clinical manifestations

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...

Acute Coronary SyndromeI: Introduction

Acute Coronary SyndromeI: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...

Acute Coronary Syndrome III: Diagnostic studies

Acute Coronary Syndrome III: Diagnostic studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...

Search research articles

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Predictive And Prognostic Markers
Safety And Efficacy Of Pcsk9 Inhibitors And Effect On Coronary Plaque Phenotype In Statin-treated Patients Following Acute Coronary Syndrome: A Systematic Review And Meta-analysis.

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Predictive And Prognostic Markers
Safety And Efficacy Of Pcsk9 Inhibitors And Effect On Coronary Plaque Phenotype In Statin-treated Patients Following Acute Coronary Syndrome: A Systematic Review And Meta-analysis.

Related Experiment Video

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

Safety and efficacy of PCSK9 inhibitors and effect on coronary plaque phenotype in statin-treated patients following acute coronary syndrome: a systematic review and meta-analysis.

Dennis Ievan Hakim¹, Faqrizal Ria Qhabibi^2,3, Muhammad Yusuf¹

¹Medical School Department, Faculty of Medicine, Brawijaya University, Jl. Veteran, Lowokwaru, Malang, 65145, Indonesia.

The Egyptian Heart Journal : (EHJ) : Official Bulletin of the Egyptian Society of Cardiology

|October 4, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Keywords:

Acute coronary syndrome Atherosclerosis LDL-C Proprotein convertase subtilisin/kexin type 9

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

Related Experiment Videos

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

Adding PCSK9 inhibitors to statin therapy significantly improves plaque characteristics and lipid profiles in acute coronary syndrome (ACS) patients. This combination therapy also reduces serious adverse events, enhancing overall safety and efficacy.

Area of Science:

Cardiovascular Medicine
Pharmacology
Interventional Cardiology

Background:

Acute coronary syndrome (ACS) remains a major cardiovascular challenge.
Statins are standard for lowering LDL-C and stabilizing plaques, but their efficacy is limited.
PCSK9 inhibitors are increasingly considered as an adjunct to statin therapy for ACS patients.

Purpose of the Study:

To assess the safety and effectiveness of PCSK9 inhibitors in statin-treated ACS patients.
To investigate the impact of PCSK9 inhibitors on coronary plaque characteristics.
To evaluate changes in lipid profiles and adverse events.

Main Methods:

Systematic literature search of PubMed, Cochrane, and ProQuest.
Inclusion of trials and observational studies comparing PCSK9 inhibitors plus statins versus statins alone.

Random-effect model used for pooled analysis of plaque phenotype, lipid profiles, and safety outcomes.

Main Results:

PCSK9 inhibitors significantly improved plaque phenotype, including reduced atheroma volume and increased fibrous cap thickness.
Substantial improvements observed in all lipid profiles (P < 0.00001).
No significant difference in non-serious adverse events, but a significant reduction in serious adverse effects (RR 0.77; P = 0.04).

Conclusions:

Adding PCSK9 inhibitors to statin therapy offers significant benefits for ACS patients.
Improved plaque stability and lipid profiles contribute to enhanced efficacy.
The combination therapy demonstrates a favorable safety profile, particularly regarding serious adverse events.